Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617402 | 0.95 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL21764574 | 0.91 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL6671116 | 0.90 | CYP3A4 (0.42) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL21764814 | 0.88 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL21764586 | 0.88 | LPAR3 (0.59) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL1194563 | 0.88 | LPAR3 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL28478944 | 0.87 | CYP3A4 (0.40) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL17686773 | 0.86 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 | |
| SCHEMBL9463219 | 0.86 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 | |
| SCHEMBL393907 | 0.86 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109922841-A | The method for manufacturing implantation material with the calcium carbonate composite powder with micro-structural particle | 卡尔·莱宾格医疗技术有限责任两合公司 | 2019-06-21 | — | — | CN | claimed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3984540-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | Aequor, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
| CN-109922841-A | The method for manufacturing implantation material with the calcium carbonate composite powder with micro-structural particle | 卡尔·莱宾格医疗技术有限责任两合公司 | 2019-06-21 | — | — | CN | disclosed |
| CN-109789247-A | Contain the implantation material for inhibiting calcium carbonate | 卡尔莱布宁医疗技术有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109689123-A | The implantation material of the composite powder containing calcium salt with the particle for structure | 卡尔莱布宁医疗技术有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-109689122-A | The method of the implantation material of calciferous composite powder of the manufacture comprising the micro-structural particle with inhibition calcium carbonate | 卡尔·莱宾格医疗技术有限责任两合公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-109661419-A | Inhibiting calcium carbonate additives | 谢菲尔考克有限两合公司 | 2019-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | CYP3A4 2361/4885LPAR3 3397/4885LPAR1 3108/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | CYP3A4 1048/4885LPAR3 1324/4885LPAR1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.